Levaquin[R] receives FDA approval for treatment of chronic bacterial prostatitis.(New Products)(Brief Article)

Urologic Nursing, April, 2004

The U.S. Food and Drug Administration (FDA) has approved Levaquin[R] (levofloxacin) Tablets/Injection and Levaquin[R] (levofloxacin in 5% dextrose) Injection for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis. Chronic bacterial prostatitis is a recurrent or persistent infection of the prostate gland and the number one reason men under the age of 50 visit a urologist. With this indication, Levaquin becomes the only once-daily fluoroquinolone indicated to treat chronic bacterial prostatitis.

Levaquin is marketed by OrthoMcNeil Pharmaceutical, Inc. Chronic bacterial prostatitis is the tenth indication for Levaquin since it was first approved by the FDA in 1997.

Levaquin is...